In this webinar, a panel of experts will discuss whether autologous therapies here to stay; if allogeneic therapies are the future; and the unlimited scope of gene editing technologies.
Lomecel-B – Longeveron’s proprietary off-the-shelf cell therapy for aging frailty – failed the six-minute walk test (6MWT) endpoint of a Phase IIb study, according to a statement published by the Miami-based biotech on Aug. 13.
Cell and gene therapies (C>s) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C>s are continuing to expand, there is a widening gap between the potential of treatment advances and the patient experience. The industry is beginning to acknowledge the problems faced in one of healthcare’s most complex areas for patient experience, according to EmerGENE’s Nareda Mills (Global President Patient Solutions) and Ben Beckley (Global Lead).
Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.
Ashfield, part of UDG Healthcare plc, announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries.
Washington D.C.-based global science and technology innovator Danaher announced a definitive agreement to acquire Aldevron for $9.6 billion.
Working through two subsidiaries, life sciences giant Bayer is taking multiple shots at Parkinson’s disease. In addition to Bayer’s efforts to tackle Parkinson’s, Adhera Therapeutics announced that the company will acquire a new class of drug aimed at the disease.
Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.
BioSpace takes a look at a few of the highlights of the 24th annual meeting of the ASGCT, with researchers presenting cutting-edge work in the booming area of gene and cell therapy.
France-based Genfit launched NASHnext, a novel, non-invasive diagnostic test for nonalcoholic steatohepatitis (NASH) powered by the company’s proprietary diagnostic technology, NIS4. The test is offered in the United States through Labcorp.
